CD106 (VCAM-1) Monoclonal Antibody (429), FITC, eBioscience™, Invitrogen™

Description

• Description: The 429 monoclonal antibody reacts with mouse CD106 (Vascular Cell Adhesion Molecule-1, VCAM-1), a 110 kDa transmembrane glycoprotein expressed by myeloid lineage and bone marrow stromal cells
• Endothelial cells constitutively express low levels of CD106 and upregulate it upon cytokine stimulation
• CD106 binds to integrin alpha4beta1 (VLA-4, CD49d/CD29) and Integrin a4b7 (LPAM-1) and these interactions in the bone marrow and thymus are important for early lymphocyte and myeloid development
• Cytokine-mediated upregulation of CD106 on endothelial cells suggests a role for this antigen in the inflammatory response
• Applications Reported: The 429 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The 429 antibody has been tested by flow cytometric analysis of mouse bone marrow cells
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• VCAM-1 is a cell surface sialoglycoprotein expressed by cytokine activated endothelium
• The protein has a number of functions including the regulation of leukocyte migration, leukocyte-endothelial cell adhesion and signal transduction and may play a role in a number of inflammatory diseases.